Subject    :    [2018 Dec;42(6)] The Prevalence and Risk Factors for Diabetic Retinopathy in Shiraz, Southern Iran
Writer KDA
Date 2019-03-06 10:15:03 Hit 137
Diabetes Metab J. 2018 Dec;42(6):538-543. English.
Published online Aug 09, 2018.  https://doi.org/10.4093/dmj.2018.0047 
Copyright © 2018 Korean Diabetes Association
   
The Prevalence and Risk Factors for Diabetic Retinopathy in Shiraz, Southern Iran
Haleh Ghaem,1 Nima Daneshi,2 Shirin Riahi,3 and Mostafa Dianatinasab4
1Research Center for Health Sciences, Institute of Health, Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
2Behbahan Faculty of Medical Sciences, Behbahan, Iran.
3Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
4Center for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Iran.

Corresponding author: Nima Daneshi. Behbahan Faculty of Medical Sciences, Behbahan, Iran. Email: daneshi.nima@gmail.com 
 
Received March 19, 2018; Accepted April 26, 2018.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

 
Abstract

Globally, diabetic retinopathy (DR) is one of the leading causes of blindness, that diminishes quality of life. This study aimed to describe the prevalence of DR, and its associated risk factors. This cross-sectional study was carried out among 478 diabetic patients in a referral center in Fars province, Iran. The mean±standard deviation age of the participants was 56.64±12.45 years old and DR prevalence was 32.8%. In multivariable analysis, lower education levels (adjusted odds ratio [aOR], 0.43; 95% confidence interval [CI], 0.24 to 0.76), being overweight (aOR, 1.70; 95% CI, 1.02 to 2.83) or obese (aOR, 1.88; 95% CI, 1.09 to 3.26), diabetes duration of 10 to 20 years (aOR, 2.35; 95% CI, 1.48 to 3.73) and over 20 years (aOR, 5.63; 95% CI, 2.97 to 10.68), receiving insulin (aOR, 1.99; 95% CI, 1.27 to 3.10), and having chronic diseases (aOR, 1.71; 95% CI, 1.02 to 2.85) were significantly associated with DR. In conclusion, longer diabetes duration and obesity or having chronic diseases are strongly associated with DR suggesting that control of these risk factors may reduce both the prevalence and impact of retinopathy in Iran.

   
Keywords:
DiabetesDiabetes durationDiabetic retinopathyInsulinPrevalenceRisk factors
 

Articles - Reviews in DMJ
No. Subject Date Hit ↓
Notice : [2019 June;43(3)] Serum R-Spondin 1 Is a New Surrogate Marker for Obesity and Insulin Resistance [2019 June;43(3)] Serum R-Spondin 1 Is a New Surrogate Marker for Ob... 2019-06-28 355
Notice : [2019 June;43(3)] Association of Visit-to-Visit Variability of Blood Pressure with Cardiovascular Disease among Type 2 Diabetes Mellitus Patients: A Cohort Study [2019 June;43(3)] Association of Visit-to-Visit Variability of Blood... 2019-06-28 363
Notice : [2019 June;43(3)]  Oral Glucose Tolerance Testing Allows Better Prediction of Diabetes in Women with a History of Gestational Diabetes Mellitus [2019 June;43(3)] Oral Glucose Tolerance Testing Allows Better Pred... 2019-06-28 357
Notice : [2019 June;43(3)] Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study [2019 June;43(3)] Diabetes Mellitus and Cause-Specific Mortality: A ... 2019-06-28 354
Notice : [2019 June;43(3)]  Effectiveness of Exercise Intervention in Reducing Body Weight and Glycosylated Hemoglobin Levels in Patients with Type 2 Diabetes Mellitus in Korea: A Systematic Review and Meta-Analysis [2019 June;43(3)] Effectiveness of Exercise Intervention in Reducin... 2019-06-28 356
Notice : [2019 June;43(3)] Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study [2019 June;43(3)] Acarbose Add-on Therapy in Patients with Type 2 Di... 2019-06-28 361
Notice : [2019 June;43(3)] Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial [2019 June;43(3)] Efficacy and Safety of Voglibose Plus Metformin in... 2019-06-28 349
Notice : [2019 June;43(3)] Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets [2019 June;43(3)] Understanding Bile Acid Signaling in Diabetes: Fro... 2019-06-28 349
Notice : [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Primary Cause of Adipose Tissue Inflammation [2019 June;43(3)] Mitochondrial Dysfunction in Adipocytes as a Prima... 2019-06-18 547
292 [2019 Apr;43(2)] Associations between Breastfeeding and Type 2 Diabe... 2019-04-18 1,405
291 [2019 Apr;43(2)] Increased Nociceptive Responses in Streptozotocin-I... 2019-04-18 1,109
290 [2019 Apr;43(2)] The Risk of Myocardial Infarction and Ischemic Stro... 2019-04-18 1,181
289 [2019 Apr;43(2)] Myricetin Protects Against High Glucose-Induced ... 2019-04-18 1,118
288 [2019 Apr;43(2)] Association between Changes in Anthropometric Indic... 2019-04-18 1,090
287 [2019 Apr;43(2)] Discrepancies between Glycosylated Hemoglobin and F... 2019-04-18 1,121
286 [2019 Apr;43(2)] Predictors of the Therapeutic Efficacy and Consider... 2019-04-18 1,089
285 [2019 Apr;43(2)] Metabolic Consequences of Obstructive Sleep Apnea E... 2019-04-18 1,096
284 [2019 Apr;43(2)] Nonalcoholic Fatty Liver Disease and Diabetes: Part... 2019-04-18 1,083
283 [2019 Feb;43(1)] Higher High Density Lipoprotein 2 (HDL2) to Total H... 2019-03-06 202

목록

Gets the previous 5 pages.   Go to previous page.  [1]   2   3   4   5     Go to next page. Gets the next  5 pages.